Charting a course for the expanded application of mRNA vaccine technology

A pioneer in the development of mRNA technology, CureVac has spent more than two decades in exploring its potential in both prophylactic and therapeutic vaccine settings. David McCall, Senior Editor, Nucleic Acid Insights, discusses the promise of next-generation approaches with Chief Development Officer, Myriam Mendila.

Please enter your email to access content Read now